The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Pivotal Phase III Trial of Two Dose Levels of Denileukin Diftitox for the Treatment of Cutaneous T-Cell Lymphoma
Abstract
PURPOSE: The objective of this phase III study was to determine the efficacy, safety, and pharmacokinetics of denileukin diftitox (DAB 389 IL-2, Ontak [Ligand Phar-maceuticals Inc, San Diego, CA]) in patients with stage Ib to IVa cutaneous T-cell lymphoma (CTCL) who have previously received other therapeutic interventions. PATIENTS AND METHODS: Patients with biopsy-proven CTCL that expressed CD25 on ≥ 20% of lymphocytes were assigned to one of two dose levels (9 or 18 μg/kg/d) of denileukin diftitox administered 5 consecutive days every 3 weeks for up to 8 cycles. Patients were monitored for toxicity and clinical efficacy, the latter assessed by changes in disease burden and quality of life measurements. Antibody levels of antidenileukin diftitox and anti–interleukin-2 and serum concentrations of denileukin diftitox were also measured. RESULTS: Overall, 30% of the 71 patients with CTCL treated with denileukin diftitox had an objective response (20% partial response; 10% complete response). The response rate and duration of response based on the time of the first dose of study drug for all responders (median of 6.9 months with a range of 2.7 to more than 46.1 months) were not statistically different between the two doses. Adverse events consisted of flu-like symptoms (fever/chills, nausea/vomiting, and myalgias/arthralgias), acute infusion-related events (hypotension, dyspnea, chest pain, and back pain), and a vascular leak syndrome (hypotension, hypoalbuminemia, edema). In addition, 61% of the patients experienced transient elevations of hepatic transaminase levels with 17% grade 3 or 4. Hypoalbuminemia occurred in 79%, including 15% with grade 3 or 4 changes. Tolerability at 9 and 18 μg/kg/d was similar, and there was no evidence of cumulative toxicity. CONCLUSION: Denileukin diftitox has been shown to be a useful and important agent in the treatment of patients whose CTCL is persistent or recurrent despite other therapeutic interventions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The IL-2/IL-2 receptor system: A current overview
Taniguchi, T. (1993) · Cell · doi:10.1016/0092-8674(93)90152-g · Cited by 761
Robb, R. J., & Greene, W. C. (1987) · The Journal of experimental medicine · doi:10.1084/jem.165.4.1201 · Cited by 234
Bacha, P., Williams, D. P., Waters, C., Williams, J. M., Murphy, J. R., & Strom, T. B. (1988) · The Journal of experimental medicine · doi:10.1084/jem.167.2.612 · Cited by 220
Self-citationWilliams, D. P., Snider, C. E., Strom, T. B., & Murphy, J. R. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)38482-0 · Cited by 185
LeMaistre, C. F., Saleh, M. N., Kuzel, T. M., Foss, F. M., Platanias, L. C., Schwartz, G. N., Ratain, M. J., Rook, A. H., Freytes, C. O., Craig, F. E., et al. (1998) · PubMed · doi:10.1182/blood.v91.2.399 · Cited by 184
Self-citationAntitumor activity of DAB389 IL-2 fusion toxin in mycosis fungoides
Saleh, M. N., LeMaistre, C. F., Kuzel, T. M., Foss, F. M., Platanias, L. C., Schwartz, G. N., Ratain, M. J., Rook, A. H., Freytes, C. O., Craig, F. E., et al. (1998) · Journal of the American Academy of Dermatology · doi:10.1016/s0190-9622(98)70403-7 · Cited by 137
Self-citationMycosis fungoides and the Sézary syndrome: Pathology, staging, and treatment
Hoppe, R. T., Wood, G. S., & Abel, E. (1990) · Current Problems in Cancer · doi:10.1016/0147-0272(90)90018-l · Cited by 125
Self-citationSausville, E. A., Worsham, G. F., Matthews, M. J., Makuch, R., Fischmann, A. B., Schechter, G., Gazdar, A. F., & Bunn, P. A. (1985) · Human Pathology · doi:10.1016/s0046-8177(85)80177-5 · Cited by 125
Interleukin 2 receptor gamma chain expression on resting and activated lymphoid cells.
Nakarai, T., Robertson, M. J., Streuli, M., Wu, Z., Ciardelli, T. L., Smith, K. A., & Ritz, J. (1994) · The Journal of Experimental Medicine · doi:10.1084/jem.180.1.241 · Cited by 117
Waters, C. A., Schimke, P. A., Snider, C. E., Itoh, K., Smith, K. A., NICHOLS, J. C., Strom, T. B., & Murphy, J. R. (1990) · European Journal of Immunology · doi:10.1002/eji.1830200412 · Cited by 114
Self-citationMycosis fungoides: clinical and histologic features, staging, evaluation, and approach to treatment
Abel, E., Wood, G. S., & Hoppe, R. T. (1993) · CA A Cancer Journal for Clinicians · doi:10.3322/canjclin.43.2.93 · Cited by 70
Self-citation
Cited by
Drug Delivery Systems: Entering the Mainstream
Allen, T. M., & Cullis, P. R. (2004) · Science · doi:10.1126/science.1095833 · Cited by 4,552
Tenchov, R., Bird, R., Curtze, A. E., & Zhou, Q. (2021) · ACS Nano · doi:10.1021/acsnano.1c04996 · Cited by 2,221
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Olsen, E., Vonderheid, E., Pimpinelli, N., Willemze, R., Kim, Y., Knobler, R., Zackheim, H., Duvic, M., Estrach, T., Lamberg, S., et al. (2007) · Blood · doi:10.1182/blood-2007-03-055749 · Cited by 1,429
Self-citation
Metadata
- Authors
- Olsen, E., Duvic, M., Frankel, A., Kim, Y., Martin, A., Vonderheid, E., Jegasothy, B., Wood, G., Gordon, M., Heald, P., Oseroff, A., Pinter-Brown, L., Bowen, G., Kuzel, T., Fivenson, D., Foss, F., Glode, M., Molina, A., Knobler, E., Stewart, S., Cooper, K., Stevens, S., Craig, F., Reuben, J., Bacha, P., & Nichols, J.
- Venue
- Journal of Clinical Oncology
- Published
- 2001-01-15
- Volume
- 19
- Issue
- 2
- Pages
- 376-388
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1895474562
- Cited by
- 609
- References
- 11
- FWCI
- 36.40
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.